The U.S. FDA granted Signum Surgical Ltd. de novo marketing clearance for its Biohealx technology as a treatment for anal fistula. Biohealx is a single use, bioabsorbable implant, designed to not only ...
Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch GALWAY, Ireland--(BUSINESS WIRE)-- Signum Surgical, a medical technology company dedicated to advancing the ...
A consortium of Birmingham researchers, clinicians and industry partners has received a second £1.1m award from the National Institute for Health and Care Research (NIHR) for a three-year study ...
- Medtech expert to drive commercialization of BioHealx ® for the treatment of anal fistula. GALWAY, Ireland--(BUSINESS WIRE)--Signum Surgical, (‘Signum’ or ‘the Company’) the medical technology ...
Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx (R)Anal Fistula Device - offering new hope ...
Signum Surgical, a medical technology company dedicated to advancing the treatment of colorectal diseases, today announced the publication of first-in-human clinical data for its BioHealx® Anal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback